Do fewer cases of Kaposi's sarcoma in HIV-infected patients reflect a decrease in HHV8 seroprevalence?

Area of Science:

• Virology
• Immunology
• Epidemiology

Background:

• Human herpes virus 8 (HHV8) is the causative agent of Kaposi's sarcoma (KS).
• HHV8 seroprevalence is notably higher in individuals with human immunodeficiency virus (HIV) infection.
• The decreased incidence of KS may be linked to improved HIV treatment and immune status or reduced HHV8 prevalence.

Purpose of the Study:

• To ascertain HHV8 antibody prevalence in HIV-positive versus HIV-negative patients at University Hospital Frankfurt/Main, Germany.
• To compare current findings with historical data to track trends in HHV8 infection spread.
• To investigate the relationship between HHV8 seroprevalence, HIV status, and clinical Kaposi's sarcoma incidence.

Main Methods:

• Analysis of 100 serum samples from HIV-positive patients and 100 from HIV-negative controls.
• Detection of HHV8 antibodies using an IgG immunofluorescence assay.
• Statistical comparison of seroprevalence rates between groups and across age demographics.

Main Results:

• Overall HHV8 seroprevalence was 16%, with no significant gender-based differences.
• A significant disparity in HHV8 seroprevalence was observed: 30% in HIV-infected patients versus 2% in HIV-negative controls.
• The highest seroprevalence in HIV-positive individuals occurred in the 40-49 age group (42%), with the lowest in the 20-29 group (16.6%).
• Comparison with previous studies indicated a clear increase in HHV8 seroprevalence among HIV-infected patients.

Conclusions:

• HHV8 seroprevalence has increased in HIV-infected patients in Germany.
• The observed low incidence of clinical Kaposi's sarcoma is likely attributed to enhanced immunological status resulting from optimized anti-HIV therapies.
• Continued monitoring of HHV8 prevalence in vulnerable populations is warranted.